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Abstract
Background: The accumulation of protease resistant conformers of the prion protein (PrP
res) is a key pathological feature of
prion diseases. Polyanions, including RNA and glycosaminoglycans have been identified as factors that contribute to the
propagation, transmission and pathogenesis of prion disease. Recent studies have suggested that the contribution of these
cofactors to prion propagation may be species specific.
Methodology/Principal Finding: In this study a cell-free assay was used to investigate the molecular basis of polyanion
stimulated PrP
res formation using brain tissue or cell line derived murine PrP. Enzymatic depletion of endogenous nucleic
acids or heparan sulphate (HS) from the PrP
C substrate was found to specifically prevent PrP
res formation seeded by mouse
derived PrP
Sc. Modification of the negative charge afforded by the sulphation of glycosaminoglycans increased the ability of
a familial PrP mutant to act as a substrate for PrP
res formation, while having no effect on PrP
res formed by wildtype PrP. This
difference may be due to the observed differences in the binding of wild type and mutant PrP for glycosaminoglycans.
Conclusions/Significance: Cofactor requirements for PrP
res formation are host species and prion strain specific and affected
by disease associated mutations of the prion protein. This may explain both species and strain dependent propagation
characteristics and provide insights into the underlying mechanisms of familial prion disease. It further highlights the
challenge of designing effective therapeutics against a disease which effects a range of mammalian species, caused by
range of aetiologies and prion strains.
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Introduction
Transmissible spongiform encephalopathies (TSE) or prion
diseases are a group of invariably fatal neurodegenerative
disorders associated with misfolded conformers (PrP
Sc) of the
normal cellular prion protein (PrP
C). In animals the disease occurs
naturally as scrapie in sheep, bovine spongiform encephalopathy
(BSE) in cattle and chronic wasting disease (CWD) in deer and elk.
In humans the disease occurs in sporadic, familial and acquired
forms with phenotypes including Creutzfeldt-Jakob Disease,
Gerstmann-Stra ¨ussler-Scheinker syndrome (GSS) and Fatal Fa-
milial Insomnia [1]. The transmissible nature of prion disease has
been attributed to the template directed misfolding of PrP
C, which
is supported by the absolute requirement of PrP
C expression for
disease transmission and pathogenesis [2]. The protein only
hypothesis proposes that PrP
Sc is the principal component of this
infectious agent or template [3]. However, it is not clear whether
PrP
Sc is the only component of the infectious and/or pathogenic
entity.
Cell-free models of template directed PrP
C misfolding (or
conversion to PrP
Sc) have demonstrated that PrP
Sc can induce a
conformational change in PrP
C, rendering it protease resistant
(referred to as PrP
res) [4,5,6] and infectious under prescribed
conditions [7]. Previously, the efficiency of this process using
partially purified constituents has been low, often requiring a large
excess of PrP
Sc, which has been proposed to reflect the need for a
catalytic co-factor in the process [8,9]. This view is further
supported by the low levels of infectivity produced by folding
recombinant PrP into a protease resistant form, although this may
also reflect the absence of post-translational modification of the
recombinant protein and the nature of the transgenic mouse
model used in the bioassay [9,10].
The reported ability of polyanions to stimulate the misfolding of
partially purified mammalian or recombinant PrP
C and generate
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Sc seed provides
compelling evidence for the role of a cofactor for the acquisition of
prion infectivity [11,12]. Negatively charged macromolecules or
polyanions, including nucleic acids [11,12,13,14,15,16,17,18,
19,20], phospholipids [21,22,23,24] and glycosaminoglycans
(GAGs) have been implicated as facilitating cofactors in the
conversion of PrP
C to PrP
Sc and thereby in the transmission and
pathogenesis of prion disease. Mechanistically, GAGs have been
proposed to act as scaffolds to support the misfolding of PrP
C [25].
Further, GAGs have been reported to act as receptors for PrP
Sc on
the cell surface [26,27], affect PrP
C trafficking [28,29,30] and are
also found in PrP
Sc associated plaques [31,32]. Treatments, which
modify the GAG content of prion infected cells, or treatment of
infected cells with GAGs (or GAG mimetics) have been shown to
clear prion infection [28,33]. Pentosan polysulphate (PPS), a
heparan sulphate mimetic, can prolong incubation time in prion
infected mice [34] and is currently being used on a compassionate
basis in variant CJD [35,36]. Significantly, unlike RNA, GAGs are
found at the cell surface and along the endosomal pathway where
PrP
Sc formation has been proposed to occur [25].
Whilst the ability of polyanions to stimulate PrP
res formation in
cell-free assays and from recombinant PrP appears to be species
independent [14,37,38,39], PrP
res formation following the specific
depletion of polyanions from the PrP
C substrate appears to be host
species specific [40]. Using a cell-free model to investigate reaction
conditions and cofactors affecting the susceptibility of a murine
PrP
C substrate to seeded PrP
res formation, we report here that
PrP
res formation is significantly and specifically inhibited by the
degradation of endogenous nucleic acids or heparan sulphate. We
further show that treatment to modify the degree of GAG
sulphation has a differential effect on the ability of wild-type PrP
and PrP encoding a mutation associated with familial prion disease
to act as a substrate for conversion to PrP
res. This may be
attributed to the differing ability of wild-type and mutant PrP
C to
bind to GAGs, suggesting that cellular cofactors differentially
modulate sporadic and familial forms of prion disease and
implicates subtle changes in the GAG repertoire in the
pathogenesis of prion disease.
Results
Heparan sulphate and electrostatic involvement in cell
free PrP
res formation
The Conversion Activity Assay (CAA) generates PrP
res from a
PrP
C substrate derived from an uninfected brain homogenate
(UBH) seeded with a prion infected brain homogenate (IBH).
Using the M1000 mouse adapted prion strain [41] as the IBH
seed, PrP
res formation occurs in a time (Figure 1A) and PrP
C
dependent manner with PrP
res generated from the balb/c (WT)
but not Prnp
2/2 (KO) mouse brain homogenates (Figure 1B).
While the PrP
C contained within the WT UBH was efficiently
converted, there is evidence of further limiting, non-PrP factors in
the process as only a small proportion of the available PrP
C
substrate (2469%, n=8) is converted in the reaction using UBH
derived from PrP
C over expressing Tga20 mice [42]. That an
increase in PrP
C does not significantly increase conversion
efficiency suggests that factors other than PrP
C in the UBH may
limit the output of the assay (Figure 1B).
Electrostatic forces mediate many biological interactions
[43,44,45] and have been reported to affect the folding and
stability of PrP [46]. To investigate whether electrostatic forces
play a role in the cell-free formation of PrP
res the CAA was
performed in buffers of increasing ionic strength (Figure 2A).
Using a similar assay, the ability of IBH derived PrP
Sc to drive the
amplification of PrP
res has been shown to decrease in the absence
of NaCl [47]. However, the interaction was also significantly
reduced in high ionic strength buffers ($300mM; p,0.01 one-way
ANOVA analysis relative to125mM NaCl), consistent with a
Figure 1. Conversion activity of brain derived PrP
C in the CAA seeded with infected brain homogenates. (A) UBH from balb/c (WT) mice
were subjected to the CAA in the presence of IBH for differing periods of time (0–24 hours). B) The CAA was performed for 16 hours using IBH added
to DPBS, or UBH from KO, WT or PrP over expressing Tga20 (TG) mice. DPBS represents total (DPBS
2 without PK treatment), and protease resistant
(DPBS
+ with PK treatment) PrP present in the IBH used to seed the CAA. Relative PrP
C expression (without PK treatment) is shown in right of panel for
KO, WT and TG mice. Conversion activity was determined as the fold increase in immunoreactive signal of WT relative to KO reactions after overnight
(or as indicated) incubation at 37uC and treatment with PK (100mg/ml, 1hr at 37uC). Blots developed with 03R19. Molecular weights (kDa) are shown.
Western blots are representative of replicated experiments, quantification is based on at least three experiments, mean and SEM are shown. *p,0.05,
**p,0.01, ***p,0.001 using one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test (GraphPad, Prism).
doi:10.1371/journal.pone.0012351.g001
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interactions in the seeded formation of PrP
res.
Electrostatic interactions may exist between polyanionic mole-
cules, such as sulphated GAG (sGAG) species and the polybasic
regions of PrP [48,49,50]. The contribution of sGAG to PrP
res
formation using the CAA described here was investigated by
specific depletion of the endogenous sGAG content of the UBH
used as the PrP
C substrate in the CAA (Figure 2B). Following
optimisation of the conditions required for efficient sGAG
digestion, the presence of sulphated species in the UBH was
decreased (Figure 2C) and a reduction of polysaccharide chains
shown by decreased absorbance of purified GAGs separated using
an anion exchange column (Figure 2D). The capacity of the UBH
to act as a conversion substrate in the CAA was specifically and
significantly (p,0.001) reduced following heparinase III treatment
to preferentially degrade heparan sulphate but not other sulphated
GAG species, including heparin and chondroitin sulphate species.
Treatment to deplete GAGs from the substrate did not reduce the
amount of available PrP
C substrate (data not shown).
It has been previously reported that the conversion activity of
263K, a hamster adapted sheep scrapie strain, is decreased by
enzymatic treatment to reduce the nucleic acid content [14] and
recently suggested that nucleic acids do not contribute to the
conversion activity of mouse adapted prion strains [40]. To
determine if this is true of all mouse prion strains the CAA was
performed using the M1000 strain of mouse adapted human
prions. The effect of MgCl2 concentration, a divalent cation
required for the efficient activity of the nucleic acid digesting
enzyme, Benzonase was first investigated to ensure that the effect
of the treatment was enzyme specific (Figure 3A). It was found that
concentrations of MgCl2 required for optimal activity of
Benzonase (1–2mM) did not significantly affect conversion activity,
while concentrations at or over 5mM significantly decreased
conversion activity. Benzonase treatment of the mouse derived
Figure 2. Conversion activity of brain derived PrP
C in the CAA seeded with infected brain homogenates is sensitive to ionic
strength and inhibited by the specific depletion of heparan sulphate. (A) The CAA was performed using IBH diluted in UBH prepared from
WT and KO mice in Tris-HCl pH 7.4 and the indicated concentrations of NaCl. ** Indicates a significant reduction in conversion activity relative to
125mM NaCl. B) The CAA was performed using IBH diluted in UBH prepared from WT mice in 125mM NaCl/Tris-HCl pH 7.4 after treatment with
Heparinase I (H), Heparinase III (HS), Chondroitinase ABC (Ch), their corresponding buffers (underlined) or without treatment (Con). Conversion
activity was determined as the fold increase in immunoreactive signal of WT relative to KO reactions after overnight incubation at 37uC and treatment
with PK (100mg/ml, 1hr at 37uC). Quantification (A, B) is based on at least three experiments, mean and SEM are shown. **p,0.01, ***p,0.001 using
one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test (GraphPad, Prism). C) The amount of sGAG purified from UBH treated
with Heparinase I (H), Heparinase III (HS) and Chondrotinase ABC (Ch) or untreated (Con) was determined by Blyscan analysis and normalised to the
amount of sGAG recovered from buffer controls (not shown). D) The absorbance (254nm) of sGAG eluted from a Q-Sepharose HiTrap anion exchange
column in increasing concentrations of NaCl (0–1M). GAGs were purified from control (%), Heparinase I treated (e) and Heparinase III treated (#)o r
Chondroitinase ABC treated (+) brain homogenates. Quantification (C, D) is based on an analysis performed in duplicate.
doi:10.1371/journal.pone.0012351.g002
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buffer control, whereas pre-treatment of the IBH seed of the CAA
had no effect (Figure 3B). This suggests that nucleic acids present
in the UBH substrate, but not the IBH seed, can act as catalysts or
scaffolds for PrP
res formation.
Familial prion disease mutations affect sGAG binding and
conversion activity of PrP
C in the CAA
Mutations associated with familial prion disease located in the
C-terminal region of PrP (121–231) do not reduce the stability
of PrP [51]. However, the proline to leucine mutation at residue
101 of full length mouse PrP (P102L human PrP sequence) has
been reported to alter the alpha-helical content of full length
PrP [52] and this and other familial mutations have been
reported to increase the GAG binding capacity of PrP [53].
Expression of endogenous levels of 101L mutation are not
sufficient to induce spontaneous disease in knock-in mice,
although the mutation does alter the susceptibility of mice to
prion infection [54]. To investigate how GAGs may affect the
susceptibility of the 101L mutation to undergo seeded misfold-
ing we developed a CAA model using mouse PrP
C exogenously
expressed in RK13 cells as the substrate (Figure 4). RK13 cells
do not express detectable levels of PrP, but become susceptible
to infection by mouse adapted prion strains through exogenous
expression of mouse PrP [55,56,57]. When lysates of mouse
PrP
C expressing cells were used as the substrate in the CAA a
significant increase in PrP
res was detected relative to RK-13 cells
that had been transfected with the empty expression vector
(puroRK). This exogenous expression system also enabled the
investigation of the conversion activity of moPrP harbouring a
P101L mutation (Figure 4A). The conversion activity of
reactions containing mutant 101L-moPrP was significantly
greater than those of wild-type 101P-moPrP, despite detection
of lower 101L-moPrP levels (Figure 4B).
To investigate whether the association of sGAG with PrP
C
affects the conversion process wild-type 101P-moPrP and mutant
101L-moPrP cells were treated with chlorate, a general inhibitor of
GAG sulphation [58], and PrP
C formed in the presence of
modified GAG sulphation used as substrate in the CAA. The
conversion activity of wildtype 101P-moPrP was not significantly
affected by chlorate treatment of the cells (Figure 4A,C). In
contrast the conversion activity of mutant 101L-moPrP was
significantly increased following chlorate treatment (Figure 4A,D).
To understand the different response of 101P and 101L moPrP
to chlorate treatment we investigated their relative GAG binding
capacities. The heparin binding capacity of 101L-moPrP was
significantly greater (p,0.001, two way ANOVA) than that of
101P-moPrP (Figure 5A, C). An N-terminally truncated form of
PrP does not appreciably bind to sGAG [48], consistent with a
GAG binding site in the N-terminal region of PrP [49,50].
Mutations associated with familial prion disease have been shown
to reveal a cryptic GAG binding site down stream of the residue
90, which may enable the C2 fragment of PrP to bind to GAGs
[53]. PNGaseF treatment revealed a truncated fragment of 101L-
moPrP bound to heparin whereas the same fragment present in
the 101P-moPrP expressing cells was not detected (Figure 5B).
This fragment was detected using antibodies 03R19 but not with
the N-terminal antibody 03R17 indicating that it lacked N-
terminal residues 23–30 (data not shown).
Discussion
Large negatively charged macromolecules (GAGs, nucleic acids
and phospholipids) have been implicated in the pathogenesis of
prion diseases. Nucleic acids, and in particular RNA has been
identified as a potential co-factor in the formation of the disease
associated isoform of the prion protein, in hamster [11,14] but not
mouse models of prion disease [40]. The current study using a
Figure 3. Conversion activity in the CAA following Benzonase treatment of UBH or IBH. A) The CAA was performed in the presence of the
indicated concentrations of MgCl2 and B) performed following pre-treatment as indicated. Conversion activity was determined as the fold increase in
immunoreactive signal of treated samples relative to their equivalent KO reactions after overnight incubation at 37uC and treatment with PK (100mg/
ml, 1hr at 37uC). Quantification is based on at least three experiments, mean and SEM are shown. **p,0.001 or *p,0.05 using one-way analysis of
variance (ANOVA) with Dunnet’s test for multiple comparisons against the indicated control (GraphPad, Prism).
doi:10.1371/journal.pone.0012351.g003
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the prion strain and species specific requirements for prion
propagation. We report that depletion of either nucleic acids or
sGAG and in particular heparan sulphate, prevent the cell free
formation of PrP
res from murine PrP
C seeded with mouse derived
PrP
Sc. Changes to GAG sulphation through chlorate treatment
increased the ability of PrP
C encoding the P101L mutation linked
with familial prion disease to form PrP
res, which may be related to
the ability of this molecule to associate with under sulphated GAG
species.
Recent reports have suggested that the cofactors required for
efficient hamster PrP
res formation may be species specific as the
depletion of RNA from a murine derived substrate did not affect
PrP
res formation [14,40]. In contrast prion infectivity can been
generated from either hamster PrP or recombinant murine PrP, in
the absence of a PrP
Sc seed, by the addition of RNA, albeit in the
presence of lipids [11,12]. Thus it would appear that RNA
stimulation of de novo PrP
res formation is species independent.
Furthermore the data presented here showing that depletion of
nucleic acids from the PrP
C substrate of a mouse adapted model of
human prion disease prevented PrP
res formation, indicates that the
requirement for endogenous RNA may be prion strain dependent.
Moreover the use of a prion strain originally derived from a
patient with GSS in the current study rather than scrapie or
bovine spongiform encephalopathy strains raises the possibility
that human prion strains have different cofactor requirements to
animal prion strains. We are investigating this possibility further
using a mouse adapted prion strain developed from a T2MM
sporadic prion strain [56].
A further species or strain specific effect is raised by the
significant and specific effect of heparan sulphate depletion on
conversion activity shown here. Unlike earlier reports, in which
the heparinase III treatment did not affect the conversion activity
of a hamster PrP
C substrate seeded with 263K hamster adapted
scrapie brain homogenate [14], we show that specific depletion of
endogenous heparan sulphate inhibits the conversion activity of a
mouse PrP
C substrate when seeded with the M1000 mouse
adapted human prion strain. The curing effect of heparinase III,
but not heparinase I and chondroitinase ABC treatment of prion
infected N2a cells has been previously reported and proposed to
relate to either the relative GAG content of N2a cells or relate to
the cleavage specificity of the enzymes [30]. In particular it was
Figure 4. Conversion activity of wild-type and mutant PrP
C expressed in RK-13 cells in the CAA following chlorate treatment to
modify the sulphation of GAG. The CAA was performed using lysates prepared from RK-13 cells expressing WT (101P) and mutant (101L) moPrP.
A) Quantification of conversion activity of 101P and 101L moPrP left untreated (2) or treated with 30mM chlorate (+) or UBH (Brain). B) Western blot
analysis of PrP
C expression in 101P and 101L moPrP left untreated (2) or treated with 30mM chlorate (+). Equivalent protein loaded in each lane, blots
probed with beta-tubulin. CAA performed using (C) 101P-moPrP and (D) 101L-moPrP cells left untreated (2) or treated with 30mM chlorate (+).
Conversion activity was determined as the fold increase in immunoreactive signal relative to puroRK reactions after overnight incubation at 37uC and
treatment with PK (100mg/ml, 1hour at 37uC). Blots developed with 03R19. Molecular weight (kDa) is shown. Western blots are representative of
replicated experiments, quantification is based on at least three experiments, mean and SEM are shown. *p,0.05 two-tailed t-test of indicated pairs.
In (C) and (D) CAA performed using KO and WT mouse brain homogenates (with quantitation shown as brain in A) and cell lysate derived from
puroRK (N), 101P (P) and 101L (L) moPrP expressing cell lines. Truncated fragment (r) was not a consistently observed in either wildtype or mutant
cell lines and was not included in analysis.
doi:10.1371/journal.pone.0012351.g004
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GAGs that are the target of heparinase III or relate to the length of
the stub that survives enzymatic treatment. Our results are
consistent with a role for specific GAG sulphation patterns in the
conversion process.
In the model studied here either depletion of nucleic acids or
heparan sulphate led to the complete abolition of conversion
activity. The apparent requirement for two cofactors in PrP
res
formation is not unexpected as the formation of infectivity from
recombinant murine PrP required both RNA and lipids and the
presence of lipids in infectivity derived from RNA stimulated
mammalian PrP could not be excluded [11,12]. Glycosaminogly-
cans and nucleic acids are both large negatively charged molecules
based on an underlying carbohydrate backbone. We considered
whether the high concentrations of Benzonase used to digest the
nucleic acids as described here and in other reports (1000 times the
manufacturers’ recommended levels for general digestion of
nucleic acids) may have non-specifically affected the GAG content
of the substrate. However, in preliminary experiments to
investigate this possibility we found no definitive change in the
sulphated GAG content of homogenates following Benzonase
treatment. Therefore for this strain at least both RNA and
heparan sulphate are absolutely required for PrP
res formation.
Point mutations (including the P102L human PrP mutation,
equivalent to the P101L mouse PrP mutation studied here) and
octapeptide repeat expansions associated with familial prion
disease increase the association of recombinant PrP with sGAGs
[53]. Using PrP
C expressed in a mammalian cell line capable of
supporting prion infection [55,56,57] it was shown that the affinity
of 101L-moPrP for heparin was significantly increased relative to
wild type moPrP. This confirms that the increased affinity of
recombinant PrP encoding familial mutations for heparin [53] is
also observed for PrP expressed in mammalian systems.
The 101L-moPrP mutation was more susceptible to conversion
to PrP
res in the CAA than the wild type 101P-moPrP. As
previously reported [59], introduction of the 101L mutation
increased the protease resistance and insolubility of PrP expressed
in RK13 cells (Welton and Lawson unpublished observations).
Introduction of the same mutation does not alter the stability [60]
or confer protease resistance [52] on recombinant PrP produced in
a cofactor free environment, although the alpha helical content of
the protein is decreased. The alpha helical content of purified PrP
is decreased by binding to PPS, which has been proposed to
increase the susceptibility of the protein to conversion in cell free
assays by reducing the transition barrier [38]. We therefore
propose that subtle conformational changes associated with the
101L-moPrP [52] result in an increase in the proportion and
affinity of the 101L-moPrP population for a binding partner
(present in a mammalian expression system) and increase its ability
to convert to the PrP
res form. An alternative possibility not
investigated here is the origin of the M1000 strain from a patient
with GSS associated with the P102L mutation [61,62]. Although
adapted to mice and therefore on a wild type moPrP background
we cannot exclude the possibility that the PrP
Sc from the original
prion strain preferentially converts PrP
C encoding the original
mutation. It may also reflect a faster replication kinetics as has
been reported for PrP encoding octapeptide repeat insertions in a
cell-free conversion assay [63].
Both the P102L and E220K mutations associated with familial
prion disease do not require residues 23–27 for GAG binding, with
binding of mutant PrP
C mediated through a cryptic GAG binding
site located between residues 109–136 [53]. Consistent with this
we report the increased binding affinity of 101L-moPrP for
heparin and the preferential binding of a 22kDa fragment
consistent with C2 (89–230) from 101L but not 101P moPrP.
The association of PrP with GAGs through this alternative-
binding domain may play a role in the pathogenic process.
It was surprising that modification of GAG sulphation with
chlorate did not decrease the conversion activity of moPrP.
Chlorate treatment does not change the PK-resistance or solubility
of wild type 101P-moPrP (Welton and Lawson unpublished),
although it did increase the PrP levels, perhaps by altering the
metabolism of PrP
C [29]. Chlorate competitively inhibits the
formation of the sulphate donor 39-phosphoadenosine 59-phos-
phate (PAPS) required for GAG sulphation. When cells are grown
in medium containing normal sulphate supplementation, as
performed here, sulphation of heparan sulphate is selectively
inhibited, with 6-O-sulphation inhibited before 2-O-sulphation
[64]. Previous studies have highlighted the importance of 2-O but
not 6-O sulphation for the interaction of wildtype PrP with
heparin [49] and the role of under sulphated GAGs in prion
propagation [30]. Therefore it is possible that under the conditions
Figure 5. Binding of wild-type and mutant PrP
C expressed in
RK-13 to sGAG. A) The ability of wildtype (101P) and mutant (101L)
moPrP expressed in RK-13 cells to bind heparin sepharose beads in the
presence of increasing concentrations of NaCl (50, 100, 125, 300,
1000mM), was determined by western blot analysis. N shows neat
input. B) PrP
C bound to heparin sepharose in the presence of 50mM
NaCl was treated with PNGaseF before western blot analysis. Full length
(F) and truncated (T) PrP species are shown. C) The percentage of 101P
(dotted line) and 101L (solid line) moPrP bound to heparin sepharose in
increasing concentrations of NaCl was determined relative to binding in
50mM NaCl. Blots developed with 03R19. Molecular weight (kDa) is
shown. Western blots are representative of replicated experiments,
quantification is based on at least three experiments, mean and SEM are
shown. Binding differed significantly by Two-way ANOVA (p,0.001).
doi:10.1371/journal.pone.0012351.g005
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type 101P-moPrP with sGAG remained unaltered. Whereas due
to the altered GAG binding pattern of 101L-moPrP, selective
inhibition of sulphation may have increased the profile of GAGs
that could bind and facilitate the conversion of mutant 101L-
moPrP. Intriguingly, chlorate increased the solubility of mutant
101L-moPrP (Welton and Lawson unpublished observations),
which may have affected the ability of this species to be converted
to PrP
res.
This study has revealed a further complexity to the role of
cofactors in the propagation of prions. Although prion infectivity
can be generated from PrP in the absence of cofactors it appears
that the addition of cofactors may augment the conversion process
[9,10]. This may explain both species and strain dependent
propagation characteristics and provide insights into the underly-
ing mechanisms familial prion disease. It further highlights the
challenge of designing effective therapeutics against a disease
which effects a range of mammalian species, caused by range of
aetiologies and prion strains.
Materials and Methods
Ethics statement
The use of tissue sourced from prion infected (AEEC#04154,
0707227) and uninfected (AEEC#05090, 0810787) mice was
approved for this study by the University of Melbourne Animal
Ethics Committee
Preparation of prion infected brain homogenates (IBH)
Brains were collected from balb/c mice in the terminal stage of
disease following intracerebral inoculation with M1000 prions
[41]. For use as a seed in the cell free assay of PrP
res formation
(Conversion Activity Assay described below), 10% (w/v) brain
homogenates were prepared in calcium and magnesium free
Dulbecco’s phosphate buffered saline (DPBS) or 20 mM Tris-HCl
pH 7.4 supplemented with 1% (v/v) Triton-X 100. Homogenates
were prepared by passing tissue through a graded series of needles
(18G, 21G, 24G, 26G). The final sample was then cleared at
2006g for 2 minutes, the supernatant snap frozen in liquid
nitrogen and stored at 280uC.
Preparation of uninfected brain homogenates (UBH)
Brain tissues were collected from wild type (balb/c), Prnp knock
out (Prnp
2/2; [2]) and Prnp overexpressing (Tga20; [42]) mice.
Brain homogenates (10% w/v) were prepared in DPBS or 20mM
Tris-HCl pH 7.4 supplemented with EDTA-free ecomplete mini
protease inhibitors (PI; Roche) using a graded series of needles as
described above.
GAG lyase treatment of UBH
GAG specific lyases were obtained from Sigma. Heparinase I
and Heparinase III from Flavobacterium heparnium were prepared in
10 mM Tris-HCl pH 7.4, 4 mM CaCl2, 50mM NaCl. Chon-
droitinase ABC from Proteus vulgaris was prepared in 0.01% (w/v)
BSA. Reconstituted lyases were stored at 280uC.
UBH (50% w/v) prepared from 100 mg balb/c or Prnp
2/2
mice in 10 mM Tris-HCl pH 7.4 were treated with GAG lyase
(Heparinase I and III 20U/100 mg wet tissue equivalents;
Chondroitinase ABC 8U/100 mg wet tissue equivalents) or
dilution buffer (Heparinase Buffer, 10 mM Tris-HCl pH 7.4,
4 mM CaCl2, 50 mM NaCl; Chondroitinase Buffer 0.01% (w/v)
BSA) for 4 hours at 37uC with agitation.
Following treatment, 40 mg wet tissue equivalents was diluted
to 10% (w/v) in 20 mM Tris-HCl pH 7.4 and 125 mM NaCl
(final concentration), snap frozen in liquid nitrogen and stored at
280uC for subsequent use in the cell-free conversion activity assay
(CAA). GAGs were purified from the remaining 60 mg wet tissue
equivalents as described previously [65]. Briefly homogenates were
delipidated at room temperature for 2 hours in 4 volumes 1:2
chloroform: methanol (v/v). After centrifugation (3,0006g,
10 minutes) the pellet was dissolved in ethanol at a ratio of
1.5mL/g initial tissue equivalents to remove organic solvents. After
centrifugation (3,0006g, 10 minutes) the pellets were dried
overnight at 37uC and suspended at 1.5mL/g initial tissue
equivalents in 0.1 M Tris-HCl pH 8.0, 1mM CaCl2 and treated
with 10 mg/mL pronase (pre-incubated for 30 minutes at 60uCt o
eliminate exogenous glycosidase activity, Sigma) for 72 hours at
37uC by adding 40ml of enzyme at 0, 24 and 48 hours. The
preparation was then treated with Benzonase (0.25U/mL, Progen)
for 18 hours at 37uC, followed by 40ml pronase for a further
24 hours at 60Cu. O-linked carbohydrates were released from the
remaining peptides by titration with 10mM NaOH to pH 10–11
before the addition NaBH4 (1M) and incubation for 16 hours at
45uC. Samples were neutralized by the addition of acetic acid and
then centrifuged at 4,0006g for 15 minutes. The supernatant was
recovered and the pellet washed a further two times in purified
water, with the wash supernatant added to initial supernatant.
After the addition of 2 volumes of acetone the resulting precipitate
(4uC, for 24 hours) was recovered by centrifugation at 4,0006g for
15 minutes and was air dried and dissolved in 1mL purified water.
Purified GAGs were analyzed for their sulphated GAG
content by Blyscan analysis (Bicolor Ltd) as per the manufac-
turers instructions using Chondroitin sulphate C from shark
cartilage (Sigma) to generate a standard curve. Samples were
analyzed in triplicate using a microplate reader at a wavelength
of 650nm.
Further purification of GAG species was obtained by separation
on a 0.762.5cm Q-Sepharose HiTrap anion exchange column
(GE Healthcare). The column was prepared with 5 column
volumes of binding buffer (20mM Tris-HCl pH 7.4). Purified
GAGs were injected onto the column (1mL/minute) and washed
with 5 volumes of binding buffer to remove unbound molecules
before bound GAGs were eluted using a continuous salt gradient
(0–1M NaCl in binding buffer), 1.5mL fractions were collected at a
flow rate of 1mL/min and elution measured at an absorbance
wavelength of 256nm.
Benzonase treatment of brain homogenates
UBH and IBH prepared in DPBS were treated with Benzonase
(Merck, 1.2 mU/ml, 10 mM MgCl2, 5 minutes at 37uC). IBH
were then diluted 1 in 50 in DPBS/1% (v/v) TX-100 before use in
the Conversion Activity Assay. UBH were diluted K by the
addition of IBH in the Conversion Activity Assay.
Generation of RK13 cells expressing wildtype and mutant
mouse PrP
Wildtype mouse PrP coding sequence was cloned into the
pIRESpuro2 vector (Clontech) and verified by DNA sequencing
[57]. The P101Lmutationencoding themouse sequence equivalent
of the P102L mutation in human PrP was generated from wild-type
mouse PrP cloned into the pIRESpuro2 vector using the
Quikchange II site-directed mutagenesis kit (Stratagene) following
a modified protocol. Briefly, primers (forward, 59CCATAAT-
CAgTggAACAAgCTCAgCAAACCAAAAACC 39, reverse 59
ggTTTTTggTTTgCTgAgCTTgTTCCACTgATTATgg 39) were
designed to introduce a mismatch at residue 305, resulting in the
coding of a leucine at codon 101 instead of a proline. Thermo-
cycling was modified from the manufactures guidelines and
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cycles of denaturation at 95uC for 50 seconds, primer annealing at
60uC for 50 seconds and elongation at 68uC for 12 minutes. The
reaction was held at 68uC for 7 minutes. The vector was then
transformed and expressed as per the manufacturers directions.
Mutations were confirmed by DNA sequencing.
The constructs were transfected into RK13 cells [66,67] using
Lipofectamine2000 (Invitrogen) and stably transfected populations
of cells were selected for with puromycin (2.5mg/ml) and
designated 101P-moPrP (wildtype mo-RK13) or 101L-moPrP
(mutant mo-RK13). RK13 cells transfected with the pIRESpuro2
vector alone were used as negative controls and designated
puroRK. Cell lines were maintained at 37uCi n5 %C O 2 in
DMEM (Invitrogen) supplemented with 10% (v/v) heat-inactivat-
ed fetal calf serum (FCS) (Invitrogen), penicillin-streptomycin, L-
glutamine and puromycin (2.5mg/ml).
Cell lysates were prepared for use in the CAA by suspending 10
6
cells in 50 ml DPBS + PI and subjecting to two rounds of freeze
thawing to lyse membranes.
For heparin binding experiments, cell monolayers were washed
twice in ice cold PBS and lysed in the flask with lysis buffer
(10 mM Tris pH 8.0, 100 mM NaCl, 1% (v/v) NP-40) at 4uC.
Lysates were transferred to microfuge tubes and centrifuged for
3 minutes at 2,7006g. Total protein concentration was deter-
mined by bicinchoninic acid assay (BCA; Pierce).
Conversion Activity Assay (CAA)
To 50ml PrP
C substrate (UBH or cell lysate as prepared above),
50 ml of IBH, diluted a further 1/50 in the appropriate buffer
supplemented with 1% (v/v) Triton X-100, was added. Where the
CAA was performed in buffers of increasing ionic strength,
homogenates prepared in 20mM Tris-HCl were supplemented
with NaCl to give the final concentrations indicated. The samples
were agitated overnight at 300 rpm, 37uC. Samples were then
treated with PK (100mg/ml) for 1 hour at 37uC. The reaction was
stopped by the addition of Pefabloc SC (Roche) to 4 mM and an
equal volume of 26sample buffer added to each sample. Samples
were heated to 100uC before electrophoresis and western blot
analysis.
Western immunoblot analysis
Samples prepared in NuPAGE sample buffer (Invitrogen)
supplemented with 3% (v/v) b-mercaptoethanol were heated to
100uC and subjected to SDS-PAGE electrophoresis using
NuPAGE Novex 12% Bis Tris gels and transferred to PVDF
membranes as previously described [68]. PrP was detected with a
polyclonal antibody raised against residues 89–103 of mouse PrP
(03R19; [56]) developed with ECL-Plus chemiluminescent reagent
(GE Healthcare) and imaged using ECL Hyperfilm (GE
Healthcare) or LAS-3000 imaging system (Fuji). Deglycosylation
of samples before western blot analysis was performed by
PNGaseF treatment as previously described [56].
Chlorate treatment of cell lines
GAG sulphation was inhibited by sodium chlorate (Sigma)
treatment of RK13 cell lines as previously described [69]. Briefly,
70% confluent cells cultured in Optimem 10% FCS were treated
with 30mM sodium chlorate and maintained for 2 passages in
chlorate before cells were harvested for use in the CAA. Chlorate
treatment of RK-13 cells reduces the Alcian blue reactive species
in the conditioned medium, which is consistent with the loss of
GAG sulphation (data not shown).
Heparin binding of cell lysate derived PrP
C
Heparin-Sepharose 6 Fastflow beads (GE Healthcare, UK) were
equilibrated in lysis buffer (10 mM Tris-HCl pH 8.0, 100 mM
NaCl, 1% v/v NP-40) for 15 minutes at room temperature and
resuspended to their original volume in lysis buffer. Beads were
added to cell lysates prepared as described above (30ml bead
preparation: 400mg total protein in a final volume of 800ml lysis
buffer). In salt competition studies, lysates were prepared in the
indicated concentration of NaCl before beads and lysates were
incubated with agitation for 1–2 hour at room temperature and
then centrifuged to pellet beads. The pellet was washed 3 times in
lysis buffer and final bead pellet resuspended in 16sample buffer
and heated to 100uC before SDS-PAGE and western blot analysis.
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